Physicochemical Properties
| Molecular Formula | C29H34O5S |
| Molecular Weight | 494.64 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | IC50:2.305 µM (WRN)[1] |
| ln Vitro | WRN inhibitor 6 (compound 3ci) (0-100 µM; 72 h) induced DNA damage and apoptosis in HCT116 and SW620 cells with IC50 values of 2.305 and 16.58 µM, respectively[1]. WRN inhibitor 6 (0, 2.5, 5, 10 µM; 3, 27 h) increased the expression of p-p53, P-Chk2, and γH2AX in HCT116 cells in a dose-dependent manner[1]. |
| ln Vivo | WRN inhibitor 6 (20 mg/kg for po; 5 mg/kg for iv) has a low oral availability in mice, with an F of 11.43%, and a short intravenous half-life of 0.17 hours [1]. |
| Cell Assay |
Cell Cytotoxicity Assay[1] Cell Types: HCT116, SW620 cells Tested Tested Concentrations: 0-100 µM Incubation Duration: 72 h Experimental Results: Induced cell death with IC50s of 2.305, 16.58 µM for HCT116, SW620 cells, respectively. Western Blot Analysis[1] Cell Types: HCT116 cells Tested Tested Concentrations: 0, 2.5, 5, 10 µM Incubation Duration: 3, 27 h Experimental Results: Increased p-p53, P-Chk2, γH2AX expression in a dose-dependent manner. |
| References |
[1]. Discovery of thiophen-2-ylmethylene bis-dimedone derivatives as novel WRN inhibitors for treating cancers with microsatellite instability. Bioorg Med Chem. 2024 Feb 15;100:117588. |
Solubility Data
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0217 mL | 10.1084 mL | 20.2167 mL | |
| 5 mM | 0.4043 mL | 2.0217 mL | 4.0433 mL | |
| 10 mM | 0.2022 mL | 1.0108 mL | 2.0217 mL |